PROMO!
First order? Get 10% OFF with this code: 1storder
PROMO!
First order? Get 10% OFF with this code: 1storder
Our Product Categories
PT-141 is a synthetic peptide analogue of alpha-melanocyte-stimulating hormone (α-MSH), which is also referred to by its generic name, bremelanotide. It was created from Melanotan II and is mainly used and studied to treat sexual dysfunction in both men and women.
In contrast to other therapies, PT-141 acts as an agonist of the melanocortin receptor, selectively binding to the central nervous system’s MC3-R and MC4-R to affect sexual arousal. It has FDA approval to treat premenopausal women with hypoactive sexual desire disorder (HSDD). Its distinct mode of action keeps drawing a lot of attention for additional study.
Peptide Sequence (IUPAC Condensed): Ac-Nle-Asp(1)-His-D-Phe-Arg-Trp-Lys(1)-OH
Molecular Formula: C50H68N14O10
Molecular Weight: 1025.2 g/mol
Synonyms: Bremelanotide
View the PT-141 COAÂ
PT-141 works by activating melanocortin receptors, specifically the MC3-R and MC4-R receptors, in the central nervous system. Unlike PDE5 inhibitors that increase blood flow, however, PT-141 directly stimulates the brain pathways that control sexual arousal and desire.
Activating these receptors in the hypothalamus triggers a chain of neural signals that enhances sexual motivation. Because it acts on the central nervous system rather than the circulatory system, it provides a distinct therapeutic approach. This unique action makes it a valuable option for treating sexual dysfunction, especially hypoactive sexual desire disorder.
Buy PT-141 Peptide 10mg Vial from Peptide Works. This peptide is supplied as a lyophilized powder in sterile glass vials, offering 99% purity and packaged for precise research applications.
Treatment of Hypoactive Sexual Desire Disorder (HSDD) in Women: PT-141 (Bremelanotide) is a melanocortin receptor agonist (MC3R/MC4R) that treats hypoactive sexual desire disorder (HSDD) in women by stimulating neural pathways in the central nervous system [1]. Unlike vascular-focused treatments, it enhances sexual desire and satisfaction.
In the RECONNECT phase 3 studies, a 1.75 mg subcutaneous dose significantly improved sexual desire and reduced distress compared to placebo [2]. Preclinical and clinical studies demonstrated its ability to activate hypothalamic neurons and increase sexual arousal. Women reported higher sexual satisfaction and arousal after Bremelanotide treatment, making it a promising FDA-approved therapy for addressing the multifactorial nature of HSDD [3].
Erectile Dysfunction (ED) and Male Libido (experimental): PT-141 (Bremelanotide) shows promise as an experimental treatment for erectile dysfunction (ED), including in men unresponsive to PDE-5 inhibitors like sildenafil [4]. Studies demonstrate that subcutaneous or intranasal PT-141 induces significant erectile responses, even without visual sexual stimulation (VSS) [5].
In ED patients, doses ≥1 mg produced statistically significant results, with erections occurring within 30 minutes. Co-administration with sildenafil enhanced erectile activity compared to sildenafil alone, offering a potential alternative for patients with inadequate single-therapy responses [6]. PT-141 was well-tolerated, with common side effects like flushing and nausea, making it a promising candidate for broader ED treatment applications.
Boosts Libido, Sexual Motivation, and Arousal: Research suggests that PT-141 enhances libido, sexual motivation, and arousal by targeting central neural circuits of desire through melanocortin receptor activation (MC3R/MC4R). Unlike treatments focused solely on performance, PT-141 increases spontaneous sexual thoughts, arousal, and satisfaction, even without strong external stimuli.
Clinical studies show it improves sexual pleasure and desire in both men and women, with safe coadministration alongside ethanol. Its mechanism involves activating endogenous pathways linked to sexual arousal, making it effective for individuals unresponsive to traditional therapies like PDE-5 inhibitors. PT-141’s ability to address psychological and physiological aspects of sexual function highlights its potential as a multifaceted treatment [7].
Possible Additional Benefits (exploratory): Research suggests that PT-141 may offer additional benefits beyond sexual health, particularly in metabolism and appetite regulation. Acting as an MC4R agonist, it has been shown to promote satiety, reduce caloric intake, and support weight loss.
In clinical trials, obese women treated with PT-141 experienced significant reductions in body weight (up to 1.7 kg) and daily caloric intake (approximately 400 kcal/day) compared to placebo. While anecdotal reports suggest potential effects on mood, cognition, and inflammation, these remain unverified. PT-141’s influence on the melanocortin system highlights its exploratory potential for broader applications in energy balance and metabolic health [8].
[1] P B Molinoff 1, A M Shadiack, D Earle, et al (2003) PT-141: a melanocortin agonist for the treatment of sexual dysfunction – Annals of New York Academy of Sciences, 2003 Jun, Volume 994, Pages 96-102.
[2] A N Edinoff, N M Sanders, K B Lewis, et al (2022) Bremelanotide for Treatment of Female Hypoactive Sexual Desire – Neurology International, 2022 Jan 4, Volume 14 (Issue 1), Pages 75–88.
[3] L E Diamond, D C Earle, J R Heiman, et al (2006) An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist – Journal of Sexual Medicine, 2006 Jul, Volume 3 (Issue 4), Pages 628-638.
[4] L.E. Diamond, D.C. Earle, W.D. Garcia, and C. Spana (2005)Â Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response – Urology, Volume 65, Issue 4, April 2005, Pages 755-759.
[5] R C Rosen, L E Diamond, D C Earle, et al (2004) Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra® – International Journal of Impotence Research, volume 16, pages 135–142 (2004).
[6] L E Diamond, D C Earle, R C Rosen, et al (2004) Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction – International Journal of Impotence Research, Volume 16, pages 51–59 (2004).
[7] S Kim, M Chul Cho, S Yong Cho, et al (2020) Novel Emerging Therapies for Erectile Dysfunction – World Journal of Mens Health, 2020 Mar 16, Volume 39 (Issue 1), Pages 48–64.
[8] C Spana, R Jordan, and S Fischkoff (2022) Effect of bremelanotide on body weight of obese women: Data from two phase 1 randomized controlled trials – Diabetes Obesity & Metabolism, 2022 Mar 15, Volume 24 (Issue 6), Pages 1084–1093.
The answers to the most frequently asked questions about PT-141.
Buy PT-141 Pre-Mixed Peptide from Peptide Works. The ready-to-use pen kit includes 10mg pre-mixed cartridges with a cartridge pen, needle tips, and carry case, designed for efficient and accurate administration in research settings.
PT-141 is a synthetic peptide that activates melanocortin receptors in the brain, mainly MC3 and MC4, which help regulate arousal and desire. It works through neural pathways rather than directly increasing blood flow like traditional ED drugs. Current studies explore how this central action may influence libido and sexual response in both men and women.
Studies show PT-141 reaches peak levels about 30 minutes after administration and has a half-life of roughly 2.5 to 3 hours. Some research reports that its observed effects on arousal may continue for up to 24 to 72 hours, depending on the dose and study design. Current investigations aim to understand better how long these responses may last under controlled research conditions.
Studies exploring PT-141 report mild side effects in some participants. The most common include nausea, facial warmth, flushing, and occasional headache. A few reports note short-term changes in blood pressure or heart rate. These effects usually appear soon after dosing and tend to pass within a few hours. Research continues to evaluate its overall tolerance and safety profile.
PT-141 is not approved by the U.S. Food and Drug Administration (FDA) for human use or medical treatment. The FDA has approved only one form of bremelanotide, marketed as Vyleesi, for specific conditions in premenopausal women. Our PT-141 peptide is offered strictly for laboratory research and development, following guidelines for non-clinical, investigational study use.
This blog explores PT-141, a peptide being studied for its potential to enhance desire, motivation, and performance in men over 40. It explains how PT-141 acts in the brain, its link to dopamine pathways and its connection with oxytocin. The article also offers insight into how this peptide may help reignite passion and support overall men’s health and vitality.
This blog explores the roles of PT-141 and Kisspeptin in fertility and reproductive health. PT-141 helps enhance libido through its effects on brain pathways while Kisspeptin regulates fertility hormones through the GnRH axis. By comparing their distinct mechanisms, the article shows how these peptides work together to support hormonal balance and sexual function, offering valuable insights for ongoing research.
This blog explores the role of PT-141, oxytocin, and Kisspeptin in women’s sexual health during perimenopause. It discusses how these peptides influence libido, bonding and hormonal balance through brain pathways, offering scientific insights into innovative approaches for enhancing intimacy, desire and overall well-being during this transitional stage.
ALL CONTENT AND PRODUCT INFORMATION AVAILABLE ON THIS WEBSITE IS FOR EDUCATIONAL PURPOSES ONLY.
DISCLAIMER: These products are intended solely as a research chemical only. This classification allows for their use only for research development and laboratory studies. The information available on our Peptide Works website: https://peptide-works.com/ is provided for educational purposes only. These products are not for human or animal use or consumption in any manner. Handling of these products should be limited to suitably qualified professionals. They are not to be classified as a drug, food, cosmetic, or medicinal product and must not be mislabelled or used as such.
